"Patients with CML will take some pills and essentially live a normal life, " says Hagop Kantarjian, of M.
FORBES: Magazine Article
2.
Hagop Kantarjian, who chairs the leukemia department at the MD Anderson Cancer Center in Houston and who spearheaded the commentary piece, acknowledged that his effort may hurt his research career with the pharmaceutical industry.